Recent studies on retatrutides, a dual stimulant for GLP-1 and GIP, suggest significant outcomes in addressing excess body fat and type 2 diabetes. Initial data from clinical experiments point to notable decreases in body weight and enhanced glucose levels. Additional examination is directed on long-term harmlessness and usefulness, as well as p… Read More